Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.10 | 48.60 | 0.57% |
| CAC 40 | 7,355.37 | 72.68 | 1.00% |
| DAX 40 | 19,984.32 | 135.55 | 0.68% |
| Dow JONES (US) | 42,992.21 | 333.59 | -0.77% |
| FTSE 100 | 8,149.78 | 12.79 | 0.16% |
| HKSE | 20,090.46 | 7.83 | -0.04% |
| NASDAQ | 19,722.03 | 298.33 | -1.49% |
| Nikkei 225 | 40,281.16 | 713.10 | 1.80% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 5,970.84 | 66.75 | -1.11% |
| S&P/ASX 200 | 8,261.80 | 40.90 | 0.50% |
| SSE Composite Index | 3,400.14 | 2.07 | 0.06% |